Detalles de la búsqueda
1.
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Oncologist
; 28(5): e309-e312, 2023 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36994854
2.
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Lancet Oncol
; 23(10): 1297-1307, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36063830
3.
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Future Oncol
; 15(10): 1115-1123, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30887825
4.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 19(7): 975-986, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880291
5.
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Prostate
; 77(9): 1012-1019, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28429372
6.
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Breast Cancer Res Treat
; 163(3): 587-594, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28353061
7.
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
Prostate
; 75(12): 1329-38, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25982919
8.
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Future Oncol
; 10(6): 975-83, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24295376
9.
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care.
Prostate Cancer Prostatic Dis
; 2024 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38347113
10.
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Tumori
; 109(2): 224-232, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35400269
11.
Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal.
Cancer Metastasis Rev
; 29(2): 339-50, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20405170
12.
Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.
J Bone Oncol
; 26: 100341, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33425672
13.
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.
Ther Adv Med Oncol
; 12: 1758835920968725, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33193831
14.
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy.
J Clin Med
; 9(6)2020 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32580478
15.
Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?
Oncology
; 77 Suppl 1: 18-22, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-20130428
16.
Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
Med Oncol
; 36(9): 80, 2019 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31399784
17.
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.
Eur Urol Oncol
; 2(6): 699-707, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31542243
18.
Association among metabolic syndrome, inflammation, and survival in prostate cancer.
Urol Oncol
; 36(5): 240.e1-240.e11, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29402534
19.
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.
Sci Rep
; 7(1): 10426, 2017 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28874797
20.
Prognosis of screen-detected breast cancers: results of a population based study.
BMC Cancer
; 6: 17, 2006 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-16430776